Pregun István, Herszényi László, Juhász Márk, Miheller Pál, Tulassay Zsolt
Semmelweis Egyetem, Altalános Orvostudományi Kar II. Belgyógyászati Klinika, Budapest.
Orv Hetil. 2007 May 20;148(20):923-8. doi: 10.1556/OH.2007.27995.
The treatment of irritable bowel syndrome due to the heterogeneous clinical symptoms and coexisting psychiatric disorders is still controversial. Although several agents with different mechanisms of action are widely used in clinical practice, there are only few drugs available with strong evidence of their efficacy, safety and tolerability at present. The etiology of irritable bowel syndrome is considered to be multifactorial: experimental and clinical research on visceral hypersensitivity, motility and brain-gut axis involving its neurotransmitters and receptors created the foundation of novel therapeutic approaches. Albeit nowadays several drugs (alosetron, tegaserod) have been registered in a few countries for the treatment of irritable bowel syndrome, further large clinical trials are required related to the new chemical entities.
由于肠易激综合征临床症状的异质性以及并存的精神障碍，其治疗仍存在争议。尽管几种作用机制不同的药物在临床实践中被广泛使用，但目前仅有少数药物有充分的疗效、安全性和耐受性证据。肠易激综合征的病因被认为是多因素的：关于内脏高敏感性、动力以及涉及神经递质和受体的脑-肠轴的实验和临床研究为新的治疗方法奠定了基础。尽管目前已有几种药物（阿洛司琼、替加色罗）在一些国家获批用于治疗肠易激综合征，但仍需要针对新化学实体开展进一步的大型临床试验。
